
Scanfil Oyj

KEY DATA

PERFORMANCE



VALUATION APPROACH (EUR/SHARE)



Source: Nordea estimates

ESTIMATE CHANGES											
Year	2024E	2025E	2026E								
Sales	0%	0%	0%								
EBIT (adj)	0%	0%	0%								

Source: Nordea estimates

Nordea IB & Equity - Analysts

Pasi Väisänen Director

Sales growth guidance midpoint could be 8%

The company downgraded its 2024 guidance in December, dampening expectations for the Q4 numbers. Reported revenue growth should remain good in 2025, with the help of the SRX acquisition. Organic growth, however, could remain modest in the near term. We forecast revenue guidance of EUR 790-870m for 2025, and we believe tight cost discipline should keep the EBIT margin close to 7%. Our trimmed fair value range is EUR 8.2-10 (7.7-9.5), based on three equally weighted valuation approaches (DCF, EV/EBITDA and P/E). Revenue growth was -14% y/y in 2024 (sector average: -2%), which we think is one reason Scanfil is trading at a discount to its peer group's median valuation on 2025E-26E EV/EBIT.

We expect full-year EBIT guidance of EUR 55-61m

For Scanfil, we forecast 10% y/y lower organic revenue for Q4. Reported revenue growth in the quarter could be -6%, due to the SRX acquisition. Overall, we expect Q4 net sales of EUR 207m (LSEG Data & Analytics consensus: EUR 210m) and adjusted EBIT of EUR 14.5m (consensus: EUR 14.5m). Our dividend estimate is EUR 0.25 (consensus: EUR 0.25). We currently forecast 10% revenue growth for this year, ~5% of which is M&A-related. We also expect full-year EBIT guidance to be EUR 55-61m. Scanfil intends to change its reporting segments to geographical units in 2025.

Scanfil has a factory in the US market

Scanfil is not heavily exposed to the trade war, because it has its own assembly factory in the US. But the company could have some subcomponents (like PCB cards) produced in China, which are shipped to the US. In the future, it could use its new PCBA line in Atlanta for US sales volumes, while a factory in Suzhou could serve the Chinese market and reduce exports. The company has already decided to install two additional production lines in Malaysia, with an investment of EUR 4.3m, which it says are meant to meet the high demand. However, other explanations could be that machines at the site are old or that there is a need to produce more components outside China.

Our fair value range is EUR 8.2-10.0 per share

Scanfil is trading at a 27% discount to its peer group's median 2025E EV/EBIT valuation. A discount to the sector valuation could persist until the company's organic growth improves closer to the sector's expected sales growth average of 10% (2025).

SUMMARY TABLE - KEY FIGURES

		-					
EURm	2020	2021	2022	2023	2024E	2025E	2026E
Total revenue	595	696	844	902	775	853	900
EBITDA (adj)	55	56	63	80	74	80	84
EBIT (adj)	39	40	45	61	53	59	62
EBIT (adj) margin	6.6%	5.8%	5.4%	6.8%	6.9%	6.9%	6.9%
EPS (adj, EUR)	0.49	0.47	0.54	0.75	0.64	0.72	0.77
EPS (adj) growth	0.0%	-3.8%	14.8%	37.7%	-15.1%	13.5%	6.8%
DPS (ord, EUR)	0.17	0.19	0.21	0.23	0.25	0.27	0.29
EV/Sales	0.7	0.8	0.6	0.6	0.7	0.6	0.5
EV/EBIT (adj)	11.3	13.5	11.3	9.1	10.2	8.6	7.8
P/E (adj)	13.2	15.7	12.1	10.4	12.6	11.1	10.4
P/BV	2.3	2.3	1.9	1.9	1.8	1.6	1.5
Dividend yield (ord)	2.6%	2.5%	3.2%	2.9%	3.1%	3.4%	3.6%
FCF Yield bef A&D, lease	5.5%	-5.8%	-2.7%	8.7%	12.2%	10.0%	8.4%
Net debt	18	60	86	52	27	-9	-35
Net debt/EBITDA	0.3	1.1	1.4	0.6	0.4	-0.1	-0.4
ROIC after tax	13.9%	12.8%	11.8%	14.7%	12.6%	14.0%	14.8%

Quarterly estimates by segment

(,,, ,												
	Q123	Q223	Q323	Q423	Q124	Q224	Q324	Q424E	Q125E	Q225E	Q325E	Q425E
Industrial												
Net sales (EURm)	111.2	112.4	98.8	105.2	94.2	90.4	83.6	99.5	99.9	101.2	99.5	103.9
Sales growth y/y (%)	10%	-2%	-11%	-5%	-15%	-20%	-15%	-5%	6%	12%	19%	4%
Energy & Cleantech												
Net sales (EURm)	72.8	91.3	77.6	78.5	70.4	67.5	55.5	67.6	69.7	71.6	73.3	75.2
Sales growth y/y (%)	18%	47%	25%	15%	-3%	-26%	-28%	-14%	-1%	6%	32%	11%
Medtec & Life Science												
Net sales (EURm)	40.6	39.6	36.4	37.1	34.4	37.6	34.2	39.8	39.2	40.2	39.0	40.
Sales growth y/y (%)	21%	10%	-6%	-13%	-15%	-5%	-6%	7%	14%	7%	14%	2%
C F F C												
	Q123	Q223	Q323	Q423	Q124	Q224	Q324	Q424E	Q125E	Q125E	Q125E	Q125E
Group sales	224.6	243.3	212.8	220.8	198.9	195.5	173.3	206.9	208.8	213.0	211.7	219.8
Sales growth %	14.2%	14.3%	0.4%	-0.7%	-11.4%	-19.6%	-18.6%	-6.3%	5.0%	9.0%	22.2%	6.2%
Other operating income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.
Depreciation and amortisation	-4.7	-4.7	-4.8	-4.9	-5.0	-5.1	-5.1	-5.3	-5.4	-5.4	-5.4	-5.4
Reported EBIT	15.1	17.5	15.2	13.4	12.7	13.9	12.1	14.5	14.6	14.5	14.4	15.4
Reported EBIT margin	6.7%	7.2%	7.1%	6.1%	6.4%	7.1%	7.0%	7.0%	7.0%	6.8%	6.8%	7.0%
Group adj. EBIT	15.1	17.5	15.2	13.4	12.7	13.9	12.4	14.5	14.6	14.5	14.4	15.4
Adj. EBIT margin	6.7%	7.2%	7.1%	6.1%	6.4%	7.1%	7.2%	7.0%	7.0%	6.8%	6.8%	7.0%
Net financials	-0.6	0.9	-0.7	0.6	0.2	0.1	-0.2	-0.2	-0.2	-0.2	-0.2	-0.2
Pre-tax profit	14.5	18.4	14.5	14.0	12.9	14.0	11.9	14.2	14.4	14.3	14.2	15.3
Income tax	-2.8	-3.9	-3.5	-3.2	-3.1	-3.1	-3.1	-3.1	0.0	0.0	0.0	0.0
Tax rate %	19%	21%	24%	23%	24%	22%	26%	22%	0%	0%	0%	0%
Reported net profit for the period	11.7	14.5	11.0	10.8	9.8	10.9	8.8	11.1	11.2	11.1	11.1	11.8
Adj net profit for the period	11.7	14.5	11.0	10.8	9.8	10.9	9.1	11.1	11.2	11.1	11.1	11.8
Reported EPS	0.18	0.22	0.17	0.17	0.15	0.17	0.14	0.17	0.22	0.22	0.22	0.23
Adj. EPS	0.18	0.22	0.17	0.17	0.15	0.17	0.13	0.17	0.22	0.22	0.22	0.23

Annual estimates by segment

P&L (EURm; EPS IN EUR)									
	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Industrial									
Net sales (EURm)					438.5	427.6	367.7	404.5	426.8
Sales growth y/y (%)					n.a.	-2%	-14%	10%	5%
Energy & Cleantech									
Net sales (EURm)			135.6	182.0	254.2	320.2	261.0	289.7	305.6
Sales growth y/y (%)				34%	40%	26%	-19%	11%	5%
Medtec & Life Science									
Net sales (EURm)			107.9	120.6	151.0	153.7	146.0	159.2	167.9
Sales growth y/y (%)				12%	25%	2%	-5%	9%	5%
Group	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Net sales	563.0	579.5	595.4	695.7	843.7	901.6	774.7	853.3	900.3
Sales growth %	6.3%	2.9%	2.7%	16.8%	21.3%	6.9%	-14.1%	10.1%	5.5%
Other operating income	0.4	1.0	12.5	1.1	1.0	0.9	1.0	1.0	1.0
Depreciation and amortisation	-7.5	-15.7	-14.1	-12.6	-14.8	-16.8	-18.5	-19.7	-20.4
Reported EBIT	37.8	35.3	44.3	39.6	45.4	61.3	53.5	58.9	62.1
Reported EBIT margin	6.7%	6.1%	7.4%	5.7%	5.4%	6.8%	6.9%	6.9%	6.9%
Group adj. EBIT	37.8	38.9	39.1	40.3	45.4	61.3	53.5	58.9	62.1
Adj. EBIT margin	6.7%	6.7%	6.6%	5.8%	5.4%	6.8%	6.9%	6.9%	6.9%
Net financials	-1.7	-1.3	-2.6	-1.9	-3.7	0.3	-0.1	-0.1	-0.1
Pre-tax profit	36.1	34.0	41.7	37.7	41.7	61.6	53.3	58.8	62.0
Income tax	-7.1	-5.9	-4.8	-7.9	-6.7	-13.4	-12.4	-12.3	-12.4
Tax rate %	20%	17%	12%	21%	16%	22%	23%	21%	20%
Reported net profit for the period	29.0	28.1	36.9	29.8	35.0	48.2	40.9	46.4	49.6
Adj net profit for the period	29.0	31.7	31.7	30.5	35.0	48.2	40.9	46.4	49.6
Reported EPS	0.45	0.44	0.57	0.46	0.54	0.75	0.64	0.72	0.77
Adj. EPS	0.45	0.49	0.49	0.47	0.54	0.75	0.64	0.72	0.77

Peer group

EMS PEER GROUP: FINANCIALS

		SALES	(EURm)			GRO	WTH			EBIT M	ARGIN	
	2023	2024E	2025E	2026E	2023	2024E	2025E	2026E	2023	2024E	2025E	2026E
Hon Hai Precision Industry Co Ltd	181 989	200 008	248 383	281 983	-7%	11%	24%	14%	3%	3%	3%	3%
Delta Electronics Inc	11 849	12 431	14 277	16 054	4%	4%	15%	12%	10%	12%	13%	14%
Pegatron Corp	37 117	33 592	36 734	38 099	-5%	-11%	10%	4%	1%	1%	2%	2%
Venture Corporation Ltd	2 078	2 040	2 157	2 269	-22%	-8%	6%	5%	10%	10%	10%	10%
Universal Scientific Industrial	7 761	8 068	8 749	9 628	-11%	-1%	8%	10%	4%	3%	4%	4%
Jabil Inc	32 010	26 145	26 040	27 422	4%	-17%	-4%	5%	5%	5%	5%	6%
Compal Electronics Inc	27 959	26 787	28 536	29 777	-12%	-4%	7%	4%	1%	2%	2%	2%
Foxconn Interconnect Technology	3 802	4 359	5 395	6 379	-7%	9%	24%	18%	6%	6%	8%	8%
Inventec Corp	15 202	18 390	20 442	22 100	-5%	21%	11%	9%	1%	2%	2%	2%
Micro-Star International Co Ltd	5 404	5 892	6 632	6 970	1%	9%	13%	5%	6%	5%	6%	6%
Plexus Corp	3 983	3 548	3 948	4 320	10%	-6%	4%	9%	5%	5%	6%	6%
Note AB (publ)	382	341	364	406	15%	-8%	7%	11%	10%	9%	10%	10%
Sanmina Corp	8 453	6 780	7 868	8 413	13%	-15%	9%	7%	6%	5%	6%	6%
Incap Oyj	222	235	270	297	-16%	8%	15%	10%	13%	12%	12%	12%
Celestica Inc	7 214	9 317	10 449	12 276	10%	21%	12%	17%	5%	6%	7%	7%
SIIX Corp	1 990	1 846	1 969	2 116	12%	-1%	7%	7%	4%	0%	n.a.	n.a.
Fabrinet	2 425	2 691	3 261	3 680	17%	9%	18%	13%	11%	10%	10%	11%
Sercomm Corp	1 848	1 681	1 900	2 178	-3%	-10%	13%	15%	5%	5%	5%	5%
TT Electronics	708	636	645	674	-1%	-14%	1%	5%	8%	6%	8%	10%
Alpha Networks Inc	835	627	784	832	-16%	-26%	25%	6%	4%	0%	4%	4%
Ducommun Inc	686	762	804	856	6%	3%	6%	6%	8%	10%	11%	12%
Valuetronics Holdings Ltd	237	198	217	229	-1%	-17%	-1%	8%	5%	10%	9%	9%
Kitron ASA	775	645	679	768	21%	-17%	5%	13%	9%	8%	9%	9%
Lacroix Group SA	761	676	0	0	8%	-12%	0%	0%	2%	3%	0%	0%
Hanza AB	373	425	525	612	17%	17%	23%	17%	8%	5%	7%	8%
Group median					1.4%	-4.4%	9.2%	9.4%	5.4%	5.4%	6.4%	6.7%
Scanfil (Nordea)	844	902	775	853	6.9%	-14.1%	10.1%	5.5%	6.8%	6.9%	6.9%	6.9%
diff. from median (pp)					5.4	-9.7	1.0	-3.9	1.4	1.5	0.5	0.2

Source: LSEG Data & Analytics and Nordea estimates

EMS PEER GROUP: VALUATION

		P/E	E			EV/EB	ITDA			P/B			
	2023	2024E	2025E	2026E	2023	2024E	2025E	2026E	2023	2024E	2025E	2026E	
Hon Hai Precision Industry Co Ltd	10.4	15.1	11.7	10.2	5.0	8.5	6.9	6.0	1.6	1.5	1.3	1.2	
Delta Electronics Inc	24.5	27.2	22.2	18.8	13.2	14.2	12.0	10.6	5.4	4.7	4.2	3.7	
Pegatron Corp	14.9	14.4	13.7	12.8	8.3	7.5	6.2	6.1	1.3	1.3	1.3	1.2	
Venture Corporation Ltd	14.7	14.4	13.1	12.4	8.8	8.0	7.2	6.8	1.2	1.3	1.2	1.2	
Universal Scientific Industrial	17.4	18.9	15.4	12.4	8.9	9.7	8.4	7.2	1.8	1.9	1.8	1.6	
Jabil Inc	19.0	9.8	18.7	16.2	6.5	6.3	9.1	8.4	7.6	9.7	12.9	10.3	
Compal Electronics Inc	22.8	15.0	13.2	12.3	10.4	8.5	7.9	7.5	1.4	1.3	1.2	1.2	
Foxconn Interconnect Technology	8.3	19.8	12.6	9.1	2.8	9.4	6.5	5.2	1.5	1.4	1.2	1.1	
Inventec Corp	31.0	22.0	17.0	14.8	20.8	14.5	12.8	10.4	2.7	2.5	2.5	2.4	
Micro-Star International Co Ltd	23.0	17.6	13.7	12.4	14.5	13.2	9.8	9.1	3.1	3.0	2.7	2.4	
Plexus Corp	18.8	34.1	20.7	18.6	9.5	13.6	11.7	10.6	3.3	3.4	2.8	n.a.	
Note AB (publ)	13.5	17.2	14.5	12.5	9.0	9.2	8.6	7.6	3.1	2.8	2.3	2.0	
Sanmina Corp	10.5	17.6	14.5	12.5	5.0	7.6	7.7	7.4	1.4	2.1	2.0	1.9	
Incap Oyj	11.5	16.0	13.0	12.1	7.0	9.2	8.2	7.5	3.1	2.6	2.2	1.9	
Celestica Inc	14.4	25.6	29.9	24.6	7.0	14.4	19.0	15.9	11.6	5.6	n.a.	n.a.	
SIIX Corp	8.4	11.3	7.3	6.1	5.3	5.1	4.5	4.1	0.6	0.6	0.6	0.5	
Fabrinet	19.3	30.2	20.7	18.3	13.8	24.4	16.4	14.2	5.3	4.5	3.9	3.3	
Sercomm Corp	15.3	16.9	15.0	13.5	8.5	7.1	6.7	7.3	3.2	2.6	2.4	0.0	
TT Electronics	4.7	7.8	5.4	4.0	6.0	5.5	4.4	3.7	0.5	0.6	0.6	0.5	
Alpha Networks Inc	37.5	71.4	24.0	20.4	14.1	27.0	10.8	9.9	1.9	1.9	n.a.	n.a.	
Ducommun Inc	45.7	20.6	17.2	14.4	12.6	10.1	8.9	8.1	1.6	1.5	1.5	1.3	
Valuetronics Holdings Ltd	8.3	7.0	8.7	8.4	0.0	1.6	1.8	1.7	0.7	0.8	0.6	0.6	
Kitron ASA	11.7	20.9	16.1	13.6	8.3	11.6	10.2	9.0	4.0	3.2	2.9	2.5	
Lacroix Group SA	33.7	3.6	0.0	0.0	5.0	4.3	0.0	0.0	0.8	0.0	n.a.	n.a.	
Hanza AB	16.1	28.2	13.6	10.7	8.6	9.9	6.3	5.5	2.8	2.4	2.1	1.8	
Group average	18.2	20.1	14.9	12.8	8.8	10.4	8.5	7.6	2.9	2.5	2.5	2.0	
Scanfil (Nordea)	10.4	12.8	11.3	10.6	6.9	7.3	6.0	5.2	1.9	1.8	1.5	1.3	
diff. from average	-43%	-36%	-24%	-18%	-21%	-30%	-29%	-31%	-33%	-31%	-38%	-34%	

Source: LSEG Data & Analytics and Nordea estimates

Reported numbers and forecasts

INCOME STATEMENT											
EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Total revenue	508	530	563	580	595	696	844	902	775	853	900
Revenue growth	34.6%	4.3%	6.3%	2.9%	2.7%	16.8%	21.3%	6.9%	-14.1%	10.1%	5.5%
of which organic	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
of which FX	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBITDA	18	40	47	53	60	55	63	80	74	80	84
Depreciation and impairments PPE	-9	-7	-8	-16	-14	-13	-15	-17	-19	-20	-20
of which leased assets	0	0	0	-3	-3	-3	-3	-3	-3	-3	-3
EBITA	9	33	40	37	46	42	48	64	55	61	64
Amortisation and impairments	-2	-2	-2	-2	-2	-3	-3	-2	-2	-2	-1
EBIT	7	31	38	35	44	40	45	61	53	59	62
of which associates	0	0	0	0	0	0	0	0	0	0	0
Associates excluded from EBIT	0	0	0	0	0	0	0	0	0	0	0
Net financials	-1	1	-2	-1	-3	-2	-4	0	0	0	0
of which lease interest	0	0	0	0	0	0	0	0	0	0	0
Changes in value, net	0	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	6	33	36	34	42	38	42	62	53	59	62
Reported taxes	-6 0	-7	-7 29	-6	-5 37	-8	-7	-13	-12	-12	-12
Net profit from continued operations	0	26 0	29	28 0	37	30 0	35 0	48 0	41 0	46 0	50 0
Discontinued operations	0	0	0		0		0				0
Minority interests Net profit to equity	0	26	29	0 28	37	0 30	35	0 48	0 41	0 46	0 50
EPS, EUR	0.00	0.40	29 0.45	20 0.44	0.57	0.46	0.54	40 0.75	0.64	40 0.72	0.77
DPS, EUR	0.00	0.40	0.45	0.44	0.57	0.40	0.54	0.23	0.04	0.72	0.29
of which ordinary	0.09	0.11	0.13	0.15	0.17	0.19	0.21	0.23	0.25	0.27	0.29
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.21	0.20	0.20	0.27	0.23
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit margin in percent											
EBITDA	3.6%	7.6%	8.4%	9.1%	10.1%	7.9%	7.4%	8.9%	9.5%	9.4%	9.3%
EBITA	1.8%	6.3%	7.1%	6.4%	7.8%	6.1%	5.7%	7.1%	7.2%	7.1%	7.1%
EBIT	1.4%	5.9%	6.7%	6.1%	7.4%	5.7%	5.4%	6.8%	6.9%	6.9%	6.9%
Adjusted earnings											
EBITDA (adj)	33	40	47	53	55	56	63	80	74	80	84
EBITA (adj)	24	33	40	37	41	43	48	64	55	61	64
EBIT (adj)	22	31	38	39	39	40	45	61	53	59	62
EPS (adj, EUR)	0.24	0.36	0.45	0.49	0.49	0.47	0.54	0.75	0.64	0.72	0.77
Adjusted profit margins in percent											
EBITDA (adj)	6.6%	7.6%	8.4%	9.1%	9.3%	8.0%	7.4%	8.9%	9.5%	9.4%	9.3%
EBITA (adj)	4.8%	6.3%	7.1%	6.4%	6.9%	6.2%	5.7%	7.1%	7.2%	7.1%	7.1%
EBIT (adj)	4.4%	5.9%	6.7%	6.7%	6.6%	5.8%	5.4%	6.8%	6.9%	6.9%	6.9%
Performance metrics											
CAGR last 5 years	10.00/	24.00/	04 E0/	22.00/	0.60/	C E0/	0.00/	0.00/	6.00/	7 50/	E 20/
	19.2% -4.8%	24.0% 14.2%	24.5%	22.0%	9.6%	6.5% 24.8%	9.8%	9.9%	6.0% 6.9%	7.5% 5.9%	5.3% 8.8%
EBITDA EBIT	-4.6% -4.5%	31.0%	16.3% 26.1%	16.4% 16.8%	17.3% 25.2%	24.8% 40.5%	9.4% 7.7%	11.2% 10.2%	6.9% 8.7%	5.9%	0.0% 9.4%
EPS	-58.0%	32.7%	26.1%	15.5%	31.7%	217.8%	6.1%	10.2%	7.8%	4.7%	9.4%
DPS	-38.0 %	22.4%	20.1%	16.5%	16.3%	16.1%	13.8%	12.1%	10.8%	9.7%	8.8%
Average last 5 years	0.4 /0	22.470	21.170	10.570	10.570	10.170	13.070	12.170	10.070	9.170	0.070
Average EBIT margin	3.9%	4.5%	4.9%	4.9%	5.6%	6.4%	6.2%	6.2%	6.4%	6.4%	6.6%
Average EBITDA margin	7.7%	7.3%	7.2%	7.3%	7.9%	8.6%	8.5%	8.6%	8.7%	8.7%	8.9%
VALUATION RATIOS - ADJUSTED	EARNING	S									
EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
P/E (adj)	14.6	11.8	8.2	9.9	13.2	15.7	12.1	10.4	12.6	11.1	10.4
EV/EBITDA (adj)	7.9	7.8	5.7	6.8	8.0	9.7	8.1	6.9	7.4	6.3	5.7
EV/EBITA (adj)	10.7	9.4	6.8	9.7	10.7	12.6	10.7	8.8	9.8	8.4	7.6
EV/EBIT (adj)	11.7	10.0	7.1	9.3	11.3	13.5	11.3	9.1	10.2	8.6	7.8
VALUATION RATIOS - REPORTED											
			0040	0040		0004			00045	00055	00005
EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
P/E	n.m.	10.5	8.2	11.2	11.4	16.1	12.1	10.4	12.6	11.1	10.4
EV/Sales	0.52	0.59	0.48	0.63	0.74	0.78	0.61	0.62	0.70	0.60	0.54
EV/EBITDA	14.4	7.8	5.7	6.8	7.3	9.9	8.1	6.9	7.4	6.3	5.7
EV/EBITA	28.0	9.4	6.8	9.7	9.5	12.8	10.7	8.8	9.8	8.4	7.6
EV/EBIT	36.2	10.0	7.1	10.3	9.9	13.7	11.3	9.1	10.2	8.6	7.8
Dividend yield (ord.)	2.6%	2.6%	3.5%	3.1%	2.6%	2.5%	3.2%	2.9%	3.1%	3.4%	3.6%
FCF yield	5.8%	3.9%	8.1%	5.8%	9.3%	-5.2%	-2.1%	9.2%	8.2%	10.5%	9.0%
FCF Yield bef A&D, lease adj	5.8%	3.9%	8.1%	8.2%	5.5%	-5.8%	-2.7%	8.7%	12.2%	10.0%	8.4%
Payout ratio	37.7%	30.6%	28.6%	30.4%	34.5%	40.1%	38.6%	30.7%	39.3%	37.4%	37.6%

EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	20268
Intangible assets	27	25	22	25	23	21	19	18	17	15	1
of which R&D	n.a.	n.a.	0	0	0	0	0	0	0	0	
of which other intangibles	16	15	12	17	14	13	11	10	9	8	
of which goodwill	11	10	10	8	8	8	8	8	8	8	
Tangible assets	41	48	49	72	65	72	80	85	106	106	106
of which leased assets	0	0	0	21	18	22	24	23	23	23	2
Shares associates	n.a.	n.a.	0	1	1	1	1	1	1	1	
Interest bearing assets	0	0	0	0	0	0	0	0	0	0	(
Deferred tax assets	2	4	4	6	7	9	8	8	8	8	;
Other non-IB non-current assets	n.a.	0	0	0	0	0	0	0	0	0	
Other non-current assets	0	0	0	0	0	0	0	0	0	0	
Total non-current assets	70	77	76	103	95	102	107	112	131	129	128
Inventory	85	101	99	102	103	193	229	209	178	171	175
Accounts receivable	88	106	108	112	113	149	165	174	163	179	189
Short-term leased assets	0	0	0	0	0	0	0	0	0	0	(
Other current assets	4	2	2	3	2	4	4	3	2	3	;
Cash and bank	20	21	19	20	26	25	21	21	46	82	104
Total current assets	197	230	228	237	245	372	419	406	389	434	470
Assets held for sale	0	n.a.	n.a								
Total assets	267	307	304	340	339	474	526	518	521	563	599
Shareholders equity	108	125	145	167	183	207	227	266	292	322	354
Of which preferred stocks	n.a.	0	0	0	0	0	0	0	0	0	(
Of which equity part of hybrid debt	n.a.	0	0	0	0	0	0	0	0	0	(
Minority interest	n.a.	0	0	0	0	0	0	0	0	0	(
Total Equity	n.a.	125	145	167	183	207	227	266	292	322	354
Deferred tax	3	5	6	7	6	5	5	6	6	6	e
Long term interest bearing debt	38	27	17	25	18	42	36	0	8	13	13
Pension provisions	n.a.	0	0	0	0	0	0	0	0	0	(
Other long-term provisions	0	0	0	0	0	0	1	1	1	1	
Other long-term liabilities	0	0	0	0	0	0	0	0	0	0	(
Non-current lease debt	0	0	0	19	16	20	20	19	19	19	19
Convertible debt	n.a.	0	0	0	0	0	0	0	0	0	(
Shareholder debt	n.a.	0	0	0	0	0	0	0	0	0	(
Hybrid debt	n.a.	0 33	0 23	0 51	0 40	0	0 62	0	0 33	0 38	38
Total non-current liabilities	41	0	23	0	40	67 2	02	25 1	33	30	30
Short-term provisions	5 90	113	104	96	100	172	184	167	144	156	163
Accounts payable	90	0	0	90	4	3	4	4	4	4	103
Current lease debt Other current liabilities		n.a.	0	4	4	3 1	4	4 5	4	4 5	
Short term interest bearing debt	n.a. 22	36	33	20	6	20	46	50	42	37	3
Total current liabilities	117	149	136	122	116	199	237	227	195	203	206
Liabilities for assets held for sale	0	0	0	0	0	0	207	0	0	205	200
Total liabilities and equity	267	307	304	340	339	473	526	518	521	563	599
Balance sheet and debt metrics											
Net debt	40	43	30	46	18	60	86	52	27	-9	-35
of which lease debt	40	43	0	22	20	23	25	23	23	-9	-3
Working capital	87	96	105	118	117	173	211	214	195	192	199
Invested capital	157	173	181	221	212	275	318	325	326	321	327
Capital employed	168	188	194	233	212	293	333	339	365	395	423
ROE	0.1%	22.2%	21.5%	18.0%	21.1%	15.3%	16.1%	19.6%	14.7%	15.1%	14.7%
ROIC	10.5%	14.6%	16.5%	14.9%	13.9%	12.8%	11.8%	14.7%	12.6%	14.0%	14.8%
ROCE	18.9%	23.1%	19.8%	18.3%	17.0%	15.6%	14.5%	18.3%	15.2%	15.5%	15.2%
Net debt/EBITDA	2.2	1.1	0.6	0.9	0.3	1.1	1.4	0.6	0.4	-0.1	-0.4
Interest coverage	1.5	4.8	21.1	25.3	16.5	19.9	12.0	n.m.	n.m.	-0.1 n.m.	-0.4 n.m
Equity ratio	40.6%	4.8	47.6%	49.0%	53.9%	43.8%	43.1%	51.4%	56.1%	57.2%	59.2%
Net gearing	40.0% n.a.	34.4%	20.7%	27.7%	10.0%	28.9%	37.7%	19.4%	9.2%	-2.7%	-9.9%

CASH FLOW STATEMENT

EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
EBITDA (adj) for associates	18	40	47	53	60	55	63	80	74	80	84
Paid taxes	-5	-8	-7	-8	-7	-11	-4	-9	-12	-12	-12
Net financials	-2	-2	-2	-2	-2	-1	-2	-4	0	0	0
Change in provisions	4	-5	0	0	4	-3	0	1	0	0	0
Change in other LT non-IB	1	-2	0	-1	-1	-2	1	0	0	0	0
Cash flow to/from associates	n.a.	n.a.	0	0	0	0	0	0	0	0	0
Dividends paid to minorities	n.a.	n.a.	0	0	0	0	0	0	0	0	0
Other adj to reconcile to cash flow	7	4	0	2	-11	2	-3	3	0	0	0
Funds from operations (FFO)	23	27	39	44	43	40	53	72	61	68	71
Change in NWC	-6	-6	-10	-8	-8	-53	-43	-3	20	3	-7
Cash flow from operations (CFO)	16	21	29	36	35	-13	10	69	81	71	65
Capital expenditure	-4	-11	-10	-7	-9	-13	-19	-22	-15	-17	-18
Free cash flow before A&D	13	11	19	29	26	-25	-9	47	66	54	47
Proceeds from sale of assets	n.a.	0	0	0	13	0	0	0	0	0	0
Acquisitions	n.a.	0	0	-10	0	0	0	0	-23	0	0
Free cash flow	13	11	19	18	39	-25	-9	47	43	54	47
Free cash flow bef A&D, lease adj	13	11	19	26	23	-28	-12	44	63	52	44
Dividends paid	n.a.	-6	-7	-8	-10	-11	-12	-14	-15	-16	-17
Equity issues / buybacks	n.a.	0	0	0	0	0	0	0	0	0	0
Net change in debt	-26	-4	-14	-43	-21	39	20	-34	0	0	-4
Other financing adjustments	n.a.	n.a.	0	0	0	0	0	0	-3	-3	-3
Other non-cash adjustments	-1	-1	0	34	-3	-4	-3	2	0	0	0
Change in cash	-2	0	-1	1	5	-1	-5	0	25	36	22
Cash flow metrics											
Capex/D&A	32.3%	n.m.	n.m.	41.2%	58.4%	83.8%	n.m.	n.m.	73.6%	77.8%	82.5%
Capex/Sales	0.7%	2.0%	1.7%	1.3%	1.6%	1.9%	2.3%	2.5%	2.0%	1.9%	2.0%
Key information											
Share price year end (/current)	3	4	4	5	7	7	7	8	8	8	8
Market cap.	222	271	239	316	422	483	426	505	518	518	518
Enterprise value	262	314	269	362	440	543	511	557	544	509	483
Diluted no. of shares, year-end (m)	63.7	63.8	63.8	64.7	64.7	64.7	64.7	64.7	64.7	64.7	64.7

Disclaimer and legal disclosures

This publication or report originates from: Nordea Bank Abp, including its branches Nordea Danmark, Filial af Nordea Bank Abp, Finland, Nordea Bank Abp, filial i Norge and Nordea Bank Abp, filial i Sverige (together "Nordea") acting through their units Nordea Markets and Equity Sales & Research.

Nordea Bank Abp is supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the branches are supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the Financial Supervisory Authorities in their respective countries.

Content of report

This report has been prepared solely by Nordea Markets or Equity Sales & Research.

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

Validity of the report

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

No individual investment or tax advice

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets or Equity Sales & Research as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her

own appraisal of the tax and other financial merits of his/her investment.

Sources

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from; Nordea Markets' or Equity Sales & Research analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets or Equity Sales & Research "External Information"), Nordea Markets or Equity Sales & Research has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

Limitation of liability

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

Risk information

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

Conflicts of interest

Readers of this document should note that Nordea Markets or Equity Sales & Research has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report. Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets and Equity Sales & Research are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at www.nordea.com/mifid. Please find a list of all recommendations disseminated by Nordea Equities during the preceding 12-month period here: https://research.nordea.com/compliance

Distribution restrictions

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US or to customers in any other jurisdiction where restrictions may apply. This research report has not been prepared for distribution outside the EU, the UK or the US. The content of this research report is not a product disclosure statement or

other regulated document for the purposes of the Australian Corporations Act 2001 (CTH). The distribution of this research report in Australia has not been authorised by any regulatory authority in Australia, and Nordea bank Abp is not licensed by the Australian Securities and Investment Commission to provide financial services in Australia.

This publication or report may be distributed in the UK to institutional investors by Nordea Bank Abp London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is under supervision of the European Central Bank, Finanssivalvonta (Financial Supervisory Authority) in Finland and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available upon request.

Nordea Bank Abp ("Nordea") research is not "globally branded" research. Nordea research reports are intended for distribution in the United States solely to "major U.S. institutional investors," as defined in Rule 15a-6 under the Securities Exchange Act of 1934. Any transactions in securities discussed within the research reports will be chaperoned by Nordea Securities LLC ("Nordea Securities"), an affiliate of Nordea and a SEC registered broker dealer and member of FINRA. Nordea Securities does not employ research analysts and has no contractual relationship with Nordea that is reasonably likely to inform the content of Nordea research reports. Nordea makes all research content determinations without any input from Nordea Securities.

The research analyst(s) named on this report are not registered/qualified as research analysts with FINRA. Such research analyst(s) are also not registered with Nordea Securities and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws

Analyst Shareholding Nordea analysts do not hold shares in the companies that they cover. No holdings or other affiliations by analysts or associates.

Fair value and sensitivity

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of capital are typically the most sensitive. It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

Marketing Material

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

Market-making obligations and other significant financial interest Nordea has no market-making obligations in Scanfil Oyj shares.

As of 05/02/2025, Nordea Abp holds no positions of 0.5% or more of shares issued by Scanfil Oyj.

As of the publication of this report, the issuer does not hold a position exceeding 5% of the total shares issued in Nordea Abp.

Investment banking transactions and/or services

In view of Nordea's position in its markets, readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking and/or ancillary services to the company/ companies.

Issuer Review

This report has not been reviewed by the Issuer prior to publication.

Completion Date

06 Feb 2025, 22:23 CET

Nordea Bank Abp	Nordea Bank Abp, filial i Sverige	Nordea Danmark, Filial af Nordea Bank Abp, Finland	Nordea Bank Abp, filial i Norge
Nordea IB & Equity Division, Equity Research	Nordea IB & Equity Division, Equity Research	Nordea IB & Equity Division, EquityResearch	Nordea IB & Equity Division, Equity Research
Visiting address:	Visiting address:	Visiting address:	Visiting address:
Aleksis Kiven katu 7, Helsinki	Smålandsgatan 17	Grøniordsvei 10	Essendropsgate 7
FI-00020 Nordea	SE-105 71 Stockholm	DK-2300 Copenhagen S	N-0107 Oslo
Finland	Sweden	Denmark	Norway
Tel: +358 9 1651	Tel: +46 8 614 7000	Tel: +45 3333 3333	Tel: +47 2248 5000
Fax: +358 9 165 59710	Fax: +46 8 534 911 60	Fax: +45 3333 1520	Fax: +47 2256 8650
Reg.no. 2858394-9			

Satamaradankatu 5

Helsinki